Reduced daily risk of glycemic variability: Comparison of exenatide with insulin glargine

Diabetes Technology and Therapeutics

Volumn 11, Issue 6, 2009, Pages 339-344

  McCall, Anthony L ^a   Cox, Daniel J ^a   Brodows, Robert ^b   Crean, John ^c   Johns, Don ^b   Kovatchev, Boris ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; INSULIN GLARGINE; METFORMIN; SULFONYLUREA;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; AVERAGE DAILY RISK RANGE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH BLOOD GLUCOSE INDEX; HUMAN; INSULIN TREATMENT; INTERMETHOD COMPARISON; LOW BLOOD GLUCOSE INDEX; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SULFONYLUREA COMPOUNDS; VENOMS;

EID: 67649845862     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0107     Document Type: Article

References (33)

1. Hirsch IB, Brownlee M: Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178-181.
2. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-983.
3. Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG: Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006;29:26-31.
4. DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
5. Esposito K, Giugliano D, Nappo F, Marfella R; Companion Postprandial Hyperglycemia Study Group: Regression of carotid atherosclerosis by control of postprandial hyper-glycemia in type 2 diabetes mellitus. Circulation 2004;110: 214-219.
6. Muggeo M, Zoppini G, Bonora E, Brun E, Bonadonna RC, Moghetti P, Verlato G: Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000;23:45-50.
7. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW; Framingham Offspring Study: Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845-1850.
8. Takei Y, Tomiyama H, Tanaka N, Yamashina A: Close relationship between sympathetic activation and coronary microvascular dysfunction during acute hyperglycemia in subjects with atherosclerotic risk factors. Circ J 2007;71:202-206.
9. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 2003;290:486-494.
10. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004; 47:969-975.
11. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353: 2643-2653.
12. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group: Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial - revisited. Diabetes 2008;57: 995-1001.
13. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W: Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006;29:2433-2438.
14. Cox DJ, Kovatchev B, Julian D, Gonder-Frederick LA, Polonsky WH, Schlundt DG, Clarke WL: Frequency of severe hypoglycemia in IDDM can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab 1994;79:1659-1662.
15. Kovatchev BP, Straume M, Cox DJ, Farhy LS: Risk analysis of blood glucose data: a quantitative approach to optimizing the control of insulin dependent diabetes. J Theor Med 2000; 3:1-10.
16. Kovatchev BP, Cox DJ, Summers KH, Gonder-Frederick L, Clarke WL: Postprandial glucose dynamics and associated symptoms in type 2 diabetes mellitus. J Appl Res 2003;3: 449-458.
17. Kovatchev BP, Cox DJ, Gonder-Frederick L, Clark WL: Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabetes Technol Ther 2002;4:295-303.
18. Kovatchev BP, Cox DJ, Kumar A: Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003;5:817-825.
19. Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A: Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther 2005;7:849-862.
20. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143: 559-569.
21. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O: Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-2403.
22. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281:E155-E161.
23. Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002;87:1282-1290.
24. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089.
25. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD: Pharmacokinetics, pharmacody-namics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-181.
26. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D: Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005;7:467-477.
27. Roach P, Woodworth JR: Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Phar-macokinet 2002;41:1043-1057.
28. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
29. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000;23:1830-1834.
30. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touch-ette AD, Szwergold BS: Alpha-dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001;24:726-732.
31. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factor for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabe-tologia 1996;39:1577-1583.
32. Pyörälä M, Miettinen H, Laakso M, Pyörälä K: Hyper-insulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998;98:398-404.
33. Reichard P, Pihl M, Rosenqvist U, Sule J: Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996;39:1483-1488.